Choosing the Right Diabetic kidney disease Treatment for Type 2 Diabetes with SGLT2 Inhibitors or GLP-1s

New insights on how to individualize care for diabetic kidney disease using updated ADA guidance and trial evidence

Jun 04, 2025

∙ Paid

Topline

SGLT2 inhibitors and GLP-1 receptor agonists are now both proven to reduce the progression of chronic kidney disease (CKD) in type 2 diabetes, with the FLOW trial confirming kidney benefits for semaglutide. Choosing between the two depends on individual risk factors, comorbidities, and patient goals.

Study Details

Chronic kidney disease affects up …

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.